Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Apr 12, 2022
- Accession no.
- 0001209191-22-024129
- Filed
- Apr 12, 2022
- Trade date
- Apr 4-11, 2022
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $13.5K. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (Director & COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +3,200 | $0.98 | +$3,136 | 238,194 | Indirect | |
| Apr 6, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +1,400 | $0.95 | +$1,330 | 239,594 | Indirect | |
| Apr 8, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +1,600 | $0.76 | +$1,216 | 241,194 | Indirect | |
| Apr 11, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +8,900 | $0.88 | +$7,832 | 278,774 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.